S-1 and Irinotecan in Treating Patients Who Are Undergoing Surgery for Locally Advanced Stomach Cancer

Sponsor
Fukushima Medical University Hospital
Study ID
NCT00134095
Phase
PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
20 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • irinotecan hydrochloride — DRUG
  • tegafur-gimeracil-oteracil potassium — DRUG
  • adjuvant therapy — PROCEDURE
  • conventional surgery — PROCEDURE
  • neoadjuvant therapy — PROCEDURE

Study Details

RATIONALE: Drugs used in chemotherapy, such as S-1 and irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Giving chemotherapy before surgery may shrink the tumor so that it can be completely removed. PURPOSE: This phase II trial is studying how well giving S-1 together with irinotecan works in treating patients who are undergoing surgery for locally advanced stomach cancer.

Key Dates

Start date
Sep 30, 2004
Status verified
Jan 2010
Primary completion
Aug 31, 2008

Study Design

Enrollment
70 participants (estimated)
Primary purpose
TREATMENT

Primary Outcome Measure

Tumor shrinkage

Related Studies